ストックスクリーナーアプリを入手
39.57
2.56%
-1.04
アフターアワーズ：
39.64
0.07
+0.18%
前日終値:
$40.61
開ける：
$39.84
24時間の取引高:
3.61M
Relative Volume:
1.01
時価総額：
$94.82B
収益：
$49.41B
当期純損益:
$5.59B
株価収益率:
16.57
EPS:
2.3875
ネットキャッシュフロー:
$8.32B
1週間 パフォーマンス:
-0.43%
1か月 パフォーマンス:
-6.85%
6か月 パフォーマンス:
-17.67%
1年 パフォーマンス:
-21.83%
1日の値動き範囲:
$39.51
$40.11
1週間の範囲:
$39.07
$40.87
52週間の値動き範囲:
$39.07
$52.68
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
39.57 | 94.82B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,240.34 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.79 | 611.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
282.68 | 499.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.63 | 354.36B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.20 | 285.49B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-09 | 開始されました | Wolfe Research | Peer Perform |
| 2026-09-09 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2026-05-01 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-04-20 | ダウングレード | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2026-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2026-01-06 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-12-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-12-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-09-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-08-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-03-21 | 開始されました | Goldman | Neutral |
| 2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 繰り返されました | Argus | Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-10-30 | ダウングレード | Stifel | Buy → Hold |
| 2023-09-06 | アップグレード | Berenberg | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 再開されました | Morgan Stanley | Overweight |
| 2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-08-09 | ダウングレード | UBS | Buy → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Sell |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-03-11 | アップグレード | Goldman | Neutral → Buy |
| 2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 開始されました | Bernstein | Outperform |
| 2019-08-14 | アップグレード | UBS | Neutral → Buy |
| 2018-12-11 | アップグレード | Jefferies | Hold → Buy |
| 2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
| 2018-03-23 | アップグレード | Liberum | Hold → Buy |
| 2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
| 2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share - The Motley Fool
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Retension Pharmaceuticals Announces Pricing of Initial Public Offering - GlobeNewswire Inc.
Press Release : Availability of the aide-mémoire for Q3 2026 results - GlobeNewswire Inc.
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire » - GlobeNewswire Inc.
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Zacks Investment Research
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.
Full issuance would represent about 66.67% of Scinai (SCNI)'s depositary shares under its funding deal. - Stock Titan
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase - GlobeNewswire Inc.
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID - Finviz
RBC Capital initiates Sanofi stock at Sector Perform on transition risks - Investing.com Canada
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70%SNS Insider - GlobeNewswire Inc.
Sanofi ADSADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - ad-hoc-news.de
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
European ADRs Drift Lower In US Trading - Finimize
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - morningstar.com
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Macau Business
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - tradingview.com
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
Sanofi ADR earnings beat by $1.30, revenue topped estimates - investing.com
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews - GlobeNewswire Inc.
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire Inc.
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
0.10%
0.36%
大文字化:
|
ボリューム (24 時間):